Literature DB >> 24314385

Contact dermatitis: allergic and irritant.

Cher-Han Tan1, Sarah Rasool, Graham A Johnston.   

Abstract

Facial contact dermatitis is frequently encountered in medical practice in both male and female patients. Identifying the underlying cause can be challenging, and the causative agent may be overlooked if it is not considered during the assessment of a patient. The two main types of contact dermatitis are irritant contact dermatitis (ICD) and allergic contact dermatitis (ACD). The mechanisms and common causative agents vary for both ICD and ACD, but the clinical picture is often similar, particularly for chronic disease. Facial contact dermatitis can be successfully treated by avoiding the causative agent. In this review, we focus on the clinical assessment of a patient with facial contact dermatitis and the mechanisms of both ICD and ACD. Common causative agents, including emerging allergens, are discussed in detail, and suggestions are made regarding the management of patients with proven ICD or ACD of the face.
© 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24314385     DOI: 10.1016/j.clindermatol.2013.05.033

Source DB:  PubMed          Journal:  Clin Dermatol        ISSN: 0738-081X            Impact factor:   3.541


  23 in total

1.  Localized delivery of a lipophilic proteasome inhibitor into human skin for treatment of psoriasis.

Authors:  Meera Gujjar; Jack Arbiser; Rick Coulon; Ajay K Banga
Journal:  J Drug Target       Date:  2015-09-22       Impact factor: 5.121

2.  Skin tape stripping identifies gene transcript signature associated with allergic contact dermatitis.

Authors:  Idy Tam; Kathryn R Hill; Jin M Park; JiaDe Yu
Journal:  Contact Dermatitis       Date:  2020-12-21       Impact factor: 6.600

Review 3.  The Role of Textiles in Dermatitis: An Update.

Authors:  Motunrayo Mobolaji-Lawal; Susan Nedorost
Journal:  Curr Allergy Asthma Rep       Date:  2015-04       Impact factor: 4.806

4.  Preserving Skin Integrity with Chronic Device Use in Diabetes.

Authors:  Laurel H Messer; Cari Berget; Christie Beatson; Sarit Polsky; Gregory P Forlenza
Journal:  Diabetes Technol Ther       Date:  2018-06       Impact factor: 6.118

5.  Solenopsin A and analogs exhibit ceramide-like biological activity.

Authors:  Isabella Karlsson; Xin Zhou; Raquela Thomas; Allorie T Smith; Michael Y Bonner; Pooja Bakshi; Ajay K Banga; J Phillip Bowen; Ghassan Qabaja; Shavon L Ford; Matthew D Ballard; Kimberly S Petersen; Xuechen Li; Guangping Chen; Besim Ogretmen; Jin Zhang; E Blake Watkins; Rebecca S Arnold; Jack L Arbiser
Journal:  Vasc Cell       Date:  2015-05-08

6.  Categorization of allergic disorders in the new World Health Organization International Classification of Diseases.

Authors:  Luciana Kase Tanno; Moises A Calderon; Bruce J Goldberg; Cezmi A Akdis; Nikolaos G Papadopoulos; Pascal Demoly
Journal:  Clin Transl Allergy       Date:  2014-11-28       Impact factor: 5.871

Review 7.  Dissemination of definitions and concepts of allergic and hypersensitivity conditions.

Authors:  Luciana Kase Tanno; Moises A Calderon; Helen E Smith; Mario Sanchez-Borges; Aziz Sheikh; Pascal Demoly
Journal:  World Allergy Organ J       Date:  2016-08-09       Impact factor: 4.084

8.  Supporting the validation of the new allergic and hypersensitivity conditions section of the World Health Organization International Classification of Diseases-11.

Authors:  Luciana Kase Tanno; Moises Calderon; Pascal Demoly
Journal:  Asia Pac Allergy       Date:  2016-07-28

9.  Clinical evaluation of a water-in-oil emulsion with protective and regenerative properties for the anogenital area.

Authors:  Volkmar Küppers; Michael Kemper; Christoph Abels
Journal:  Clin Cosmet Investig Dermatol       Date:  2015-11-04

10.  Gingiva Equivalents Secrete Negligible Amounts of Key Chemokines Involved in Langerhans Cell Migration Compared to Skin Equivalents.

Authors:  Ilona J Kosten; Jeroen K Buskermolen; Sander W Spiekstra; Tanja D de Gruijl; Susan Gibbs
Journal:  J Immunol Res       Date:  2015-10-11       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.